Dr. Roberts has 25+ years of pharmaceutical research, development, corporate development, and executive experience. He is co-founder and CEO of Adaptin Bio. Prior to Adaptin Bio he was co-founder and Acting CEO of Corino Therapeutics. Dr. Roberts led and ran all activities related to Corino and the development of CRX-1008 in ATTR. He is a pharmaceutical and biotech consultant and owner of MAC B Consulting. Prior to Corino, Dr. Roberts was VP, Business Development and Corporate Officer of Chelsea Therapeutics, Inc. He was responsible for business development efforts focused primarily on licensing and M&A with consideration to pipeline management. He led the sale of Chelsea Therapeutics to H. Lundbeck A/S in 2014 for $658M. Prior to Chelsea Therapeutics, Dr. Roberts was Director of Business Development for Nektar Therapeutics’ Molecule Engineering technology and completed transactions with large and specialty pharmaceutical companies. Dr. Roberts has completed pharmaceutical transactions valued at over $1B. Dr. Roberts started his career as Manager of Biopharmaceutical Research at Shearwater Corporation where he led and was successful in the development of preclinical drug candidates from initial stages of research through Phase I clinical study, including inventing the product Movantik™. Dr. Roberts obtained his Ph.D. in Materials Science from the University of Alabama and B.S. in Chemical Engineering from Pennsylvania State University.

Simon has a career of over 30 years in drug development and commercialization. He was recently Chief Executive Officer of Nirogy. Prior he had leadership roles as; Chief Business and Strategy Officer for Athenex; President and CEO of Cellectar Biosciences; President and CEO of Chelsea Therapeutics; Global Vice President of Oncology Pharma Business and Executive Officer at Hoffmann-LaRoche. Previous positions at Roche included Life Cycle Leader and Global Project Leader of Pegasys/IFN and Head of Hepatitis Franchise. Prior, he was Clinical Leader for a number of development compounds at Roche. He has been on a number of both private and public Boards.
Early in his career he was a faculty in the Department of Pharmacology in College of Medicine at the University of Saskatchewan, where he obtained his Ph.D. in Clinical Pharmacology. During his longstanding career in pharmaceutical development, Simon had played key roles in the successful development and commercial of multiple proprietary pharmaceutical products including Tasmar®, Pegasys®, Copegus®, Northera® and Klisyri®. In addition to his Ph.D., Simon obtained a Master of Science in Toxicology from Concordia University, a Joint Honors Bachelor degree in Environmental Studies/Biology from the University of Waterloo, and he completed the Roche-sponsored Pharmaceutical Executive Management Program at Columbia Business School.

Mr. Maness has 20 years of experience in senior financial roles in the pharmaceutical industry with over 35+ years of experience in various industries. Mr. Maness currently provides consulting services to a variety of life sciences clients, both public and private, in areas including, but not limited to, IPO readiness assessments, general accounting and finance support, SEC reporting and compliance, Sarbanes-Oxley program development for internal control activities, internal audit and interim CFO roles. In 2019, acting as an interim CFO, Mr. Maness led a successful US IPO for a Canadian-based life sciences company and remains active in the public and private equity arenas for life sciences. Prior to operating his consulting business, Mr. Maness served as the Chief Financial Officer of Ballantyne Therapeutics, Inc. (now Corino Therapeutics), a pharmaceutical company, from May 2015 to April 2016. From 2006 to 2014, Mr. Maness served as the Senior Director of Finance and Corporate Controller at Chelsea Therapeutics International Inc. until the sale of the company to Lundbeck, Inc. Prior to Chelsea Therapeutics, Mr. Maness provided consulting services and held a variety of senior financial management roles, primarily in software and technology services. Mr. Maness received a B.S. in Accounting from the University of North Carolina at Charlotte and is licensed as a Certified Public Accountant and as a Chartered Global Management Accountant.

Dr. Hewitt has worked for approximately 35 years in clinical research and regulatory affairs. Most recently serving as a scientific advisor to Amneal Pharmaceuticals and Senior Scientific Advisor – Neurology at Lundbeck Pharmaceuticals. Prior to Lundbeck, Dr. Hewitt was Chief Scientific Officer for Chelsea Therapeutics where he oversaw the clinical development and regulatory approval of Northera. Prior to Chelsea, Dr. Hewitt was Director of Scientific Affairs for Amgen Canada where he oversaw the clinical research and regulatory requirements for a wide variety of proprietary biologic treatments undergoing Phase I, II and III research. Thirteen individual IND research programs were established covering the therapeutic domains of Hematology, Oncology, Neurology, Infectious Disease, and Inflammation. Dr. Hewitt also developed clinical research programs supporting the approval of three products including Neupogen, Stemgen and Infergen and six supplementary approvals. Prior to Amgen, Dr. Hewitt held positions at Jansen Pharmaceuticals and Park-Davis where he developed research programs for multiple neurology and oncology products. Prior to entering the pharmaceutical industry, he was a Lecturer at Concordia University in Montreal Canada. Dr. Hewitt obtained his Ph.D. in Pharmacology from the University of Montreal. Additionally, Dr. Hewitt received a Master of Science degree in Toxicology and a B.Sc. (Hon) in Comparative Anatomy and Physiology from Concordia University.